FY2017 Earnings Estimate for Endologix, Inc. Issued By Leerink Swann (ELGX)

Endologix, Inc. (NASDAQ:ELGX) – Equities research analysts at Leerink Swann cut their FY2017 earnings per share estimates for shares of Endologix in a research note issued on Wednesday. Leerink Swann analyst R. Misra now forecasts that the medical instruments supplier will post earnings per share of ($0.61) for the year, down from their prior forecast of ($0.60). Leerink Swann also issued estimates for Endologix’s Q4 2017 earnings at ($0.22) EPS, FY2018 earnings at ($0.52) EPS, FY2019 earnings at ($0.46) EPS and FY2020 earnings at ($0.32) EPS.

ELGX has been the subject of several other research reports. ValuEngine downgraded shares of Endologix from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded shares of Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 price objective for the company in a research note on Monday, July 24th. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Endologix in a research note on Monday, July 31st. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $5.00 target price on shares of Endologix in a report on Wednesday, September 27th. Two research analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and an average price target of $6.13.

ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Estimate for Endologix, Inc. Issued By Leerink Swann (ELGX)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://sportsperspectives.com/2017/11/11/fy2017-earnings-estimate-for-endologix-inc-issued-by-leerink-swann-elgx.html.

Endologix (NASDAQ:ELGX) opened at $5.06 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. Endologix has a 12 month low of $4.08 and a 12 month high of $10.36.

A number of hedge funds and other institutional investors have recently bought and sold shares of ELGX. Parametric Portfolio Associates LLC raised its holdings in Endologix by 30.0% during the first quarter. Parametric Portfolio Associates LLC now owns 89,748 shares of the medical instruments supplier’s stock worth $650,000 after purchasing an additional 20,685 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Endologix by 53.4% during the first quarter. JPMorgan Chase & Co. now owns 60,390 shares of the medical instruments supplier’s stock worth $438,000 after purchasing an additional 21,023 shares in the last quarter. American International Group Inc. raised its holdings in Endologix by 7.1% during the first quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after purchasing an additional 3,290 shares in the last quarter. Teachers Advisors LLC raised its holdings in Endologix by 8.4% during the first quarter. Teachers Advisors LLC now owns 141,237 shares of the medical instruments supplier’s stock worth $1,023,000 after purchasing an additional 10,924 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Endologix by 5.1% during the first quarter. Vanguard Group Inc. now owns 6,285,069 shares of the medical instruments supplier’s stock worth $45,505,000 after purchasing an additional 306,397 shares in the last quarter.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply